# Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)

> **NCT02402764** · PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 10 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT02402764
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-08
- **Primary completion:** 2016-03-10
- **Final completion:** 2019-06-06
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-09-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02402764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02402764, "Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02402764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*